+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA



Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA



International Journal of Chronic Obstructive Pulmonary Disease 14: 531-546



Current pharmacological therapies for COPD improve quality of life and symptoms and reduce exacerbations. Given the progressive nature of COPD, it is arguably more important to understand whether the available therapies are able to delay clinical deterioration; the concept of "clinically important deterioration" (CID) has therefore been developed. We evaluated the efficacy of the single-inhaler triple combination beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G), using data from three large 1-year studies. The studies compared BDP/FF/G to BDP/FF (TRILOGY), tiotropium (TRINITY), and indacaterol/glycopyrronium (IND/GLY; TRIBUTE). All studies recruited patients with symptomatic COPD, FEV1 <50%, and an exacerbation history. We measured the time to first CID and to sustained CID, an endpoint combining FEV1, St George's Respiratory Questionnaire (SGRQ), moderate-to-severe exacerbations, and death. The time to first CID was based on the first occurrence of any of the following: a decrease of ≥100 mL from baseline in FEV1, an increase of ≥4 units from baseline in SGRQ total score, the occurrence of a moderate/severe COPD exacerbation, or death. The time to sustained CID was defined as: a CID in FEV1 and/or SGRQ total score maintained at all subsequent visits, an exacerbation, or death. Extrafine BDP/FF/G significantly extended the time to first CID vs BDP/FF (HR 0.61, P<0.001), tiotropium (0.72, P<0.001), and IND/GLY (0.82, P<0.001), and significantly extended the time to sustained CID vs BDP/FF (HR 0.64, P<0.001) and tiotropium (0.80, P<0.001), with a numerical extension vs IND/GLY. In patients with symptomatic COPD, FEV1 <50%, and an exacerbation history, extrafine BDP/FF/G delayed disease deterioration compared with BDP/FF, tiotropium, and IND/GLY. The studies are registered in ClinicalTrials.gov: TRILOGY, NCT01917331; TRINITY, NCT01911364; TRIBUTE, NCT02579850.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066598251

Download citation: RISBibTeXText

PMID: 30880943

DOI: 10.2147/copd.s196383


Related references

Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respiratory Medicine 139: 65-71, 2018

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 12: 907-922, 2017

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13: 3203-3231, 2018

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17(5): 509-517, 2018

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. Erj Open Research 5(1):, 2019

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of Chronic Obstructive Pulmonary Disease 13: 3971-3981, 2018

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. International Journal of Chronic Obstructive Pulmonary Disease 10: 1093-1102, 2015

Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study. Managed Care 27(5): 40-47, 2018

Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest 155(6): 1158-1165, 2019

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. Chest 155(4): 758-770, 2019

P59Factors influencing step-up to lama+laba/ics in Copd patients initially on lama monotherapy: a thin database study. Thorax 71(Suppl 3): A116.1-A116, 2016

Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study. Respiratory Medicine 142: 73-80, 2018

LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. Evidence-BasedMedicine21(6):222, 2016

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. International Journal of Chronic Obstructive Pulmonary Disease 11: 785-797, 2016

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2: Cd012066, 2017